TrialAlzheimer's research & therapy2025

Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer's disease.

Yuqi Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.